The biology and rationale of targeting nectin-4 in urothelial carcinoma

Nature Reviews Urology, Published online: 25 November 2020; doi:10.1038/s41585-020-00394-5New and more effective treatments are urgently needed for bladder cancer. This Review discusses the role of nectin-4 as a therapeutic target for enfortumab vedotin (an antibody–drug conjugate) in locally advanced and metastatic urothelial carcinoma and outlines related clinical data.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research